Authors’ reply to Outcomes of Lynch syndrome endometrial surveillance in the Netherlands Authors: Ellis L Eikenboom, Helena C van Doorn, Anja Wagner Published: 2026 Herewith we like to address the comments regarding our recent paper, where we questioned the effectiveness of current Dutch gynaecological surveillance in a nation-wide cohort of Lynch syndrome carriers.1 First, as they point out, we did not provide data on atypical versus non-atypical hyperplasia, as in Lynch syndrome carriers we advise hysterectomy in case of hyperplasia as well, regardless of its pathological subtype. The biological behaviour of endometrial anomalies in Lynch syndrome carriers is not yet well understood and it is not known to what extent the endometrial cancer carcinogenesis pathway is similar to non-carriers. Therefore, we believe the pathological subtype of hyperplasia is irrelevant in our paper. Second, we indeed found more hyperplasia (either atypical or non-atypical) in the surveillance group (28 [16 atypical] versus 4 [1 atypical]), just as we found more endometrial carcinomas in this group. However, this does not instantly demonstrate surveillance to be effective, as the non-surveillance group did not have more advanced lesions. Although the endometrial carcinomas in the surveillance group were found slightly more often in stage 1A, this does not mean this is automatically clinically relevant, since this did not change the requisite for adjuvant therapy nor survival. Third, we indeed refrained from describing more details on surveillance and treatment for high stage and unfavourable cancers as the number of women with endometrial cancer in our cohort (who either did or did not undergo surveillance after Lynch syndrome diagnosis; 37 and 14 cases, respectively) was small and the window for inclusion and follow-up was long. During these years, changes in surveillance and treatment protocols, particularly in high stage endometrial cancer, were made. In general, endometrial cancer is detected at low stage and has a favourable prognosis. Also, a systematic review and meta-analysis of Segev et al. did not show a survival advantage in diagnosing endometrial cancer in asymptomatic patients.2 This was also seen in our cohort, where the majority of endometrial cancers was diagnosed in FIGO stage 1A. As surveillance did not significantly lead to less adjuvant therapy in FIGO stage 1 endometrial carcinomas, and also not to a significant survival benefit, we believe the current surveillance approach should at least be questioned. We would be very cautious to assume that surveillance may lead to substantially reduced morbidity based on a non-significant stage shift, similarly as we do not conclude current surveillance to be abundant based on our results. To conclusively assess the effect of surveillance on morbidity and survival, a very large, well-powered and well-defined cohort is needed. We do hope that the results of our study lead to more awareness about this topic and more (prospective) research in cohorts as ours to answer these questions. Last, we agree that it would be of interest to collect more data on which circumstances during surveillance mostly increase surveillance uptake. However, this was not the aim of our study. It could very well be that more women will choose for surveillance, when surveillance is less burdensome, but this is also a topic for further research. Conclusions on this topic cannot be based on a single institute experience as the authors suggest, since this will -by definition-not include women that refrain from visiting a gynaecologist whatsoever. In conclusion, based on our retrospective, nation-wide data, many Lynch syndrome carriers refrain from gynaecological surveillance and the effectiveness of current Dutch surveillance seems questionable. However, as mentioned in our discussion, our data should be interpreted with caution. Further large prospective studies are warranted to conclusively evaluate its effect. Contributors This Authors’ reply was formulated by Ellis L Eikenboom, Helena C van Doorn, and Anja Wagner with the approval of all authors of the original Article. Declaration of interests We declare no competing interests. References